Supriya Lifescience Ltd

Supriya Lifesci. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Supriya Lifescience Ltd

₹ 807 14.70%
22 Nov - close price
supriyalifescience.com BSE: 543434 NSE: SUPRIYA
About

Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.[1]

Key Points

Company Overview
Supriya Lifescience Limited is a generic pharmaceutical company dedicated to developing, and commercializing APIs & FDFs to treat patients with various diseases and infections, backed by strong R&D, 14 active USDMFs, 8 active CEPs & Worldwide compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA). Its focus is to develop APIs and Intermediates for both Innovators and generic companies and it also partners exclusively as CMO. [1]

Website BSE NSE
  • Market Cap ₹ 6,494 Cr.
  • Current Price ₹ 807
  • High / Low ₹ 833 / 269
  • Stock P/E 41.2
  • Book Value ₹ 113
  • Dividend Yield 0.10 %
  • ROCE 22.2 %
  • ROE 15.7 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 19.4%

Cons

  • Stock is trading at 7.17 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Allcap BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE SmallCap

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
150 117 181 101 112 105 142 132 140 140 158 161 166
70 79 106 70 84 91 87 88 108 99 103 98 101
Operating Profit 80 38 75 31 29 14 55 44 32 41 56 63 65
OPM % 53% 33% 42% 31% 25% 13% 39% 34% 23% 30% 35% 39% 39%
1 5 4 2 3 3 2 3 2 3 2 2 3
Interest 1 1 1 1 1 1 1 1 0 0 1 0 0
Depreciation 2 3 3 3 3 3 3 4 4 4 4 5 5
Profit before tax 78 40 75 30 27 13 53 43 30 40 53 60 62
Tax % 25% 1% 39% 16% 39% 25% 28% 33% 20% 26% 31% 25% 26%
58 40 46 25 17 10 38 29 24 30 37 45 46
EPS in Rs 7.96 4.93 5.74 3.14 2.09 1.18 4.75 3.54 2.97 3.70 4.59 5.55 5.73
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
184 213 278 312 391 530 461 570 625
166 191 213 213 218 316 332 394 401
Operating Profit 17 22 65 98 173 214 129 176 224
OPM % 9% 10% 23% 32% 44% 40% 28% 31% 36%
7 9 8 11 5 8 9 11 10
Interest 12 11 10 7 4 4 3 5 2
Depreciation 5 5 5 6 7 10 12 16 17
Profit before tax 8 14 57 96 167 207 123 166 215
Tax % 30% 40% 31% 24% 26% 27% 27% 28%
6 9 39 73 124 152 90 119 158
EPS in Rs 3.87 5.96 26.93 50.11 16.89 18.86 11.17 14.80 19.57
Dividend Payout % 0% 0% 0% 20% 3% 3% 5% 5%
Compounded Sales Growth
10 Years: %
5 Years: 15%
3 Years: 13%
TTM: 20%
Compounded Profit Growth
10 Years: %
5 Years: 25%
3 Years: -1%
TTM: 57%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 192%
Return on Equity
10 Years: %
5 Years: 26%
3 Years: 19%
Last Year: 16%

Balance Sheet

Figures in Rs. Crores

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 15 15 15 15 15 16 16 16 16
Reserves 31 40 79 134 254 600 683 799 890
140 130 90 82 72 27 22 5 6
55 60 69 105 105 92 98 100 101
Total Liabilities 241 245 253 336 445 735 820 921 1,012
89 91 85 99 100 190 262 310 308
CWIP 36 34 35 40 79 43 68 149 218
Investments 0 0 0 0 0 0 25 64 72
117 120 133 197 267 502 466 398 415
Total Assets 241 245 253 336 445 735 820 921 1,012

Cash Flows

Figures in Rs. Crores

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
27 28 49 117 76 49 64 113
-27 -5 5 -25 -47 -60 -124 -174
-2 -20 -50 -29 -15 150 -10 -22
Net Cash Flow -2 3 4 62 15 139 -70 -83

Ratios

Figures in Rs. Crores

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 99 92 79 60 69 79 67 71
Inventory Days 113 85 77 130 206 172 234 140
Days Payable 121 112 110 130 145 91 130 98
Cash Conversion Cycle 91 64 45 61 130 160 171 114
Working Capital Days 119 97 96 49 94 132 181 158
ROCE % 14% 37% 50% 60% 43% 19% 22%

Shareholding Pattern

Numbers in percentages

2 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
68.24% 68.24% 68.24% 68.24% 68.24% 68.28% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30%
10.30% 7.13% 5.99% 6.79% 6.24% 5.66% 5.73% 5.35% 4.56% 5.37% 4.95% 6.03%
7.90% 7.73% 10.33% 8.88% 7.89% 7.65% 7.54% 7.17% 5.39% 5.30% 5.48% 5.45%
13.56% 16.90% 15.44% 16.09% 17.62% 18.43% 18.43% 19.19% 21.77% 21.04% 21.27% 20.22%
No. of Shareholders 55,29282,57886,85394,59496,99895,60593,47892,99195,92987,98089,62185,328

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls